Industry
Biotechnology
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Loading...
Open
2.25
Mkt cap
155M
Volume
882K
High
2.32
P/E Ratio
-0.79
52-wk high
11.48
Low
2.15
Div yield
N/A
52-wk low
1.79
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 5:48 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:06 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 11:52 am
Portfolio Pulse from Avi Kapoor
July 29, 2024 | 6:31 pm
Portfolio Pulse from Avi Kapoor
July 29, 2024 | 5:19 pm
Portfolio Pulse from Avi Kapoor
July 29, 2024 | 4:03 pm
Portfolio Pulse from Vandana Singh
July 29, 2024 | 3:03 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 1:46 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 12:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.